IP Library › Granted Patent US 12,201,653
Granted Patent B2
US 12,201,653 · App. 17/747,689 · Granted Jan 21, 2025

Engineered immunostimulatory bacterial strains and uses thereof

Inventors: Christopher D. Thanos (Tiburon, CA); Laura Hix Glickman (Oakland, CA); Justin Skoble (Berkeley, CA); Alexandre Charles Michel Iannello (San Diego, CA)
Assignee: Actym Therapeutics, Inc.
A61K35/74A61K39/0275A61K39/4611A61K39/4614A61K39/4622A61K39/4644A61K39/464832A61P35/00C07K14/521C07K16/248C07K16/2818C07K16/2827C12N1/205C12N15/74A61K45/06A61K2239/50C12R2001/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,653
App. No.
17/747,689
Granted
Jan 21, 2025
Kind
B2
Abstract

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin − and/or pagP − . The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd − , purI − , and msbB − . The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Claims (33)

1. An immunostimulatory bacterium, comprising a plasmid that encodes a therapeutic product, wherein:

nucleic acid encoding the therapeutic product is under control of a eukaryotic promoter; and

the immunostimulatory bacterium comprises genome modifications, whereby the bacterium is pagP − /msbB − .

2. The immunostimulatory bacterium of claim 1 that comprises a genome modification or modifications whereby the bacterium lacks flagella, wherein the wild-type bacterium comprises flagella.

3. The immunostimulatory bacterium of claim 1 that is an adenosine auxotroph.

4. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is a protein or a nucleic acid.

5. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is an immunostimulatory protein that, when expressed in a mammalian subject, confers or contributes to anti-tumor immunity in the tumor microenvironment.

6. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is a cytokine.

7. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is selected from among one or more of: IL-2, IL-7, IL-12p70 (IL-12p40+IL-12p35), IL-15, IL-36 gamma, IL-2 that has attenuated binding to IL-2Ra, IL-15/IL-15R alpha chain complex, IL-18, IL-21, IL-23, IL-2 modified so that it does not bind to IL-2Ra, CXCL9, CXCL10, CXCL11, interferon-α, interferon-β, interferon-γ, CCL3, CCL4, CCL5, proteins that are involved in or that effect or potentiate recruitment/persistence of T cells, CD40, CD40 ligand, CD28, OX40, OX40 ligand, 4-1BB, 4-1BB ligand, members of the B7-CD28 family, CD47 antagonists, TGF-beta polypeptide antagonists, and members of the tumor necrosis factor receptor (TNFR) superfamily.

8. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is an antibody or antigen-binding fragment thereof.

9. The immunostimulatory bacterium of claim 8 , wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment that is selected from among a Fab, Fab′, F(ab′)2, single-chain Fv(scFv), Fv, dsFv, nanobody, diabody fragment, and a single-chain antibody.

10. The immunostimulatory bacterium of claim 8 , wherein the antibody or antigen-binding fragment thereof is humanized or is human.

11. The immunostimulatory bacterium of claim 8 , wherein the antibody or antigen-binding fragment thereof is an antagonist of PD-1, PD-L1, CTLA-4, VEGF, VEGFR2, or IL-6.

12. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is a cytotoxin.

13. The immunostimulatory bacterium of claim 1 , wherein the therapeutic product is a tumor antigen or a tumor neoantigen.

14. An immunostimulatory bacterium, comprising a plasmid that encodes a therapeutic product, wherein the immunostimulatory bacterium comprises one or more genome modification(s), whereby the bacterium is pagP − , msbB − , and csgD − .

15. The immunostimulatory bacterium of claim 14 , wherein the therapeutic product is under control of a eukaryotic promoter.

16. The immunostimulatory bacterium of claim 1 , wherein the bacterium is formulated for systemic administration.

17. The immunostimulatory bacterium of claim 1 that is a Salmonella species.

18. The immunostimulatory bacterium of claim 17 , wherein the immunostimulatory bacterium is a Salmonella typhimurium strain.

19. The immunostimulatory bacterium of claim 18 , wherein the Salmonella typhimurium strain is derived from a wild-type Salmonella typhimurium strain having all of the identifying characteristics of the strain deposited under ATCC accession no. 14028, or is the strain deposited under ATCC accession no. 14028.

20. The immunostimulatory bacterium of claim 1 , wherein:

the immunostimulatory bacterium is a Salmonella species; and

the immunostimulatory bacterium is an adenosine auxotroph.

21. The immunostimulatory bacterium of claim 1 , wherein the nucleic acid encoding the therapeutic product on the plasmid is operatively linked to nucleic acid encoding a secretory signal, whereby, upon expression in a host, the product is secreted.

22. The immunostimulatory bacterium of claim 1 , wherein the genome of the immunostimulatory bacterium is modified, whereby the bacterium does not express functional endogenous aspartate-semialdehyde dehydrogenase (asd).

23. The immunostimulatory bacterium of claim 22 , wherein the plasmid encodes asd.

24. The immunostimulatory bacterium of claim 1 , wherein the immunostimulatory bacterium is a strain of Salmonella, Shigella, Escherichia coli , Bifidobacteriae, Rickettsia, Vibrio, Listeria, Klebsiella, Bordetella, Neisseria, Aeromonas, Francisella, Cholera, Corynebacterium, Citrobacter, Chlamydia, Haemophilus, Brucella, Mycobacterium, Mycoplasma, Legionella, Rhodococcus, Pseudomonas, Helicobacter, Bacillus , or Erysipelothrix , or an attenuated strain thereof or a modified strain thereof of any of the preceding list of bacterial strains.

25. The immunostimulatory bacterium of claim 1 , wherein the immunostimulatory bacterium is a strain of Salmonella, Escherichia coli , or Listeria.

26. The immunostimulatory bacterium of claim 2 that comprises genome modifications whereby the bacterium is csgD − .

27. The immunostimulatory bacterium of claim 6 that comprises genome modifications whereby the bacterium is csgD − .

28. The immunostimulatory bacterium of claim 14 that comprises a genome modification or modifications whereby the bacterium lacks flagella, wherein the wild-type bacterium comprises flagella.

29. The immunostimulatory bacterium of claim 14 that is a Salmonella species.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2022
From: THANOS, CHRISTOPHER D.; GLICKMAN, LAURA HIX; SKOBLE, JUSTIN; IANNELLO, ALEXANDRE CHARLES MICHEL
To: ACTYM THERAPEUTICS, INC.
Reel/Frame 059964/0148 →
Continuity (10)
Continuation 17037455 · Sep 29, 2020
Continuation 16520155 · Jul 23, 2019
Division 16520155 · Jul 23, 2019
Continuation PCTUS2019041489 · Jul 11, 2019
Continuation PCTUS2019041489 · Jul 11, 2019
Continuation In Part 16033187 · Jul 11, 2018
Continuation In Part PCTUS2018041713 · Jul 11, 2018
Provisional Application 62828990 · Apr 3, 2019
Provisional Application 62789983 · Jan 8, 2019
Related Publication 20220280577A1 · Sep 8, 2022
References Cited (400)
US 3536809A · Applezweig · 1970 [cited by applicant]
US 3598123A · Zaffaroni · 1971 [cited by applicant]
US 3630200A · Higuchi · 1971 [cited by applicant]
US 3710795A · Higuchi et al. · 1973 [cited by applicant]
US 3845770A · Theeuwes et al. · 1974 [cited by applicant]
US 3847770A · Radlowe et al. · 1974 [cited by applicant]
US 3916899A · Theeuwes et al. · 1975 [cited by applicant]
US 3936354A · LaPointe et al. · 1976 [cited by applicant]
US 4008719A · Theeuwes et al. · 1977 [cited by applicant]
US 4044126A · Cook et al. · 1977 [cited by applicant]
US 4364923A · Cook et al. · 1982 [cited by applicant]
US 4414209A · Cook et al. · 1983 [cited by applicant]
US 4687660A · Baker et al. · 1987 [cited by applicant]
US 4769027A · Baker et al. · 1988 [cited by applicant]
US 5033252A · Carter · 1991 [cited by applicant]
US 5052558A · Carter · 1991 [cited by applicant]
US 5059595A · Le Grazie · 1991 [cited by applicant]
US 5073543A · Marshall et al. · 1991 [cited by applicant]
US 5120548A · McClelland et al. · 1992 [cited by applicant]
US 5323907A · Kalvelage · 1994 [cited by applicant]
US 5354556A · Sparks et al. · 1994 [cited by applicant]
US 5591767A · Mohr et al. · 1997 [cited by applicant]
US 5639476A · Oshlack · 1997 [cited by applicant]
US 5674533A · Santus et al. · 1997 [cited by applicant]
US 5733566A · Lewis · 1998 [cited by applicant]
US 5759808A · Casterman et al. · 1998 [cited by applicant]
US 5997881A · Powell et al. · 1999 [cited by applicant]
US 6024961A · Curtiss, III et al. · 2000 [cited by applicant]
US 6080849A · Bermudes et al. · 2000 [cited by applicant]
US 6190657B1 · Pawelek et al. · 2001 [cited by applicant]
US 6383496B1 · Curtiss, III · 2002 [cited by applicant]
US 6447784B1 · Bermudes et al. · 2002 [cited by applicant]
US 6475482B1 · Bermudes et al. · 2002 [cited by applicant]
US 6548287B1 · Powell et al. · 2003 [cited by applicant]
US 6682736B1 · Hanson et al. · 2004 [cited by applicant]
US 6863894B2 · Bermudes et al. · 2005 [cited by applicant]
US 6962696B1 · Bermudes et al. · 2005 [cited by applicant]
US 6984720B1 · Korman · 2006 [cited by applicant]
US 7083794B2 · Curtiss, III et al. · 2006 [cited by applicant]
US 7115269B2 · Darji et al. · 2006 [cited by applicant]
US 7195757B2 · Curtiss, III et al. · 2007 [cited by applicant]
US 7344710B2 · Dang et al. · 2008 [cited by applicant]
US 7354592B2 · Bermudes et al. · 2008 [cited by applicant]
US 7390646B2 · Andino-Pavlovsky et al. · 2008 [cited by applicant]
US 7452531B2 · Bermudes et al. · 2008 [cited by applicant]
US 7514089B2 · Bermudes et al. · 2009 [cited by applicant]
US 7732417B2 · Beach et al. · 2010 [cited by applicant]
US 7892740B2 · Weichselbaum et al. · 2011 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7998461B2 · Forbes et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8093025B2 · Loessner et al. · 2012 [cited by applicant]
US 8202846B2 · Hannon et al. · 2012 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8221739B2 · Leonard et al. · 2012 [cited by applicant]
US 8232259B2 · Klinman et al. · 2012 [cited by applicant]
US 8241844B2 · Bulla, Jr. et al. · 2012 [cited by applicant]
US 8383599B2 · Hannon · 2013 [cited by applicant]
US 8426375B2 · Kandimalla et al. · 2013 [cited by applicant]
US 8426675B2 · Dickins et al. · 2013 [cited by applicant]
US 8440207B2 · Bermudes · 2013 [cited by applicant]
US 8524220B1 · Bermudes · 2013 [cited by applicant]
US 8580757B2 · Federov et al. · 2013 [cited by applicant]
US 8647618B2 · Leonard et al. · 2014 [cited by applicant]
US 8647642B2 · Bermudes · 2014 [cited by applicant]
US 8679473B2 · Fensterle et al. · 2014 [cited by applicant]
US 8679767B2 · Kaur et al. · 2014 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 8822194B2 · Zhao et al. · 2014 [cited by applicant]
US 8829254B2 · Nair et al. · 2014 [cited by applicant]
US 9068187B1 · Bermudes · 2015 [cited by applicant]
US 9181546B2 · Li et al. · 2015 [cited by applicant]
US 9242000B2 · Cheresh · 2016 [cited by applicant]
US 9265804B2 · Newman · 2016 [cited by applicant]
US 9315817B2 · Bermudes · 2016 [cited by applicant]
US 9320787B2 · Gunn · 2016 [cited by applicant]
US 9415098B2 · Lubenau · 2016 [cited by applicant]
US 9421252B2 · Bermudes · 2016 [cited by applicant]
US 9453227B2 · Diamond et al. · 2016 [cited by applicant]
US 9511129B2 · Hanson · 2016 [cited by applicant]
US 9560621B2 · Li · 2017 [cited by applicant]
US 9616114B1 · Bermudes · 2017 [cited by applicant]
US 9624494B2 · Hannon et al. · 2017 [cited by applicant]
US 9731011B2 · Brahmbhatt et al. · 2017 [cited by applicant]
US 9790504B2 · Khodarev et al. · 2017 [cited by applicant]
US 9878023B1 · Bermudes · 2018 [cited by applicant]
US 10052371B2 · Newman · 2018 [cited by applicant]
US 10087451B2 · Bermudes · 2018 [cited by applicant]
US 10100314B2 · Diamond et al. · 2018 [cited by applicant]
US 10131712B2 · Rossi et al. · 2018 [cited by applicant]
US 10188722B2 · Bermudes · 2019 [cited by applicant]
US 10190145B2 · Yam et al. · 2019 [cited by applicant]
US 10195259B2 · Newman · 2019 [cited by applicant]
US 10286051B1 · Bermudes · 2019 [cited by applicant]
US 10293037B2 · Lubenau · 2019 [cited by applicant]
US 10421971B2 · Deng et al. · 2019 [cited by applicant]
US 10449237B1 · Bermudes · 2019 [cited by applicant]
US 10450353B2 · Thanos et al. · 2019 [cited by applicant]
US 10487140B2 · Aman et al. · 2019 [cited by applicant]
US 10493113B2 · Goodman et al. · 2019 [cited by applicant]
US 10500277B2 · Brahmbhatt et al. · 2019 [cited by applicant]
US 10525082B2 · Crane et al. · 2020 [cited by applicant]
US 10584339B2 · Diamond et al. · 2020 [cited by applicant]
US 10626403B2 · Bermudes · 2020 [cited by applicant]
US 10653774B2 · Dubensky, Jr. et al. · 2020 [cited by applicant]
US 10702561B2 · Goodman et al. · 2020 [cited by applicant]
US 10729731B1 · Bermudes · 2020 [cited by applicant]
US 10774354B2 · Yam et al. · 2020 [cited by applicant]
US 10821163B2 · Lubenau · 2020 [cited by applicant]
US 10828356B1 · Bermudes · 2020 [cited by applicant]
US 10961538B2 · Diamond et al. · 2021 [cited by applicant]
US 11028153B2 · Aman et al. · 2021 [cited by applicant]
US 11045504B2 · Newman · 2021 [cited by applicant]
US 11103538B2 · Forbes et al. · 2021 [cited by applicant]
US 11141492B2 · Diamond et al. · 2021 [cited by applicant]
US 11168326B2 · Thanos et al. · 2021 [cited by applicant]
US 11174486B2 · Hasty et al. · 2021 [cited by applicant]
US 11242528B2 · Thanos et al. · 2022 [cited by applicant]
US 11261219B2 · Thanos et al. · 2022 [cited by applicant]
US 11471494B2 · Falb et al. · 2022 [cited by applicant]
US 11590215B2 · Lubenau · 2023 [cited by applicant]
US 11613758B2 · Hasty et al. · 2023 [cited by applicant]
US 11723932B2 · Falb et al. · 2023 [cited by applicant]
US 11779612B2 · Thanos et al. · 2023 [cited by applicant]
US 20020026655A1 · Bermudes et al. · 2002 [cited by applicant]
US 20020086014A1 · Korman et al. · 2002 [cited by applicant]
US 20030031683A1 · Curtiss, III et al. · 2003 [cited by applicant]
US 20030109026A1 · Bermudes et al. · 2003 [cited by applicant]
US 20030170276A1 · Bermudes et al. · 2003 [cited by applicant]
US 20030175297A1 · Urashima · 2003 [cited by applicant]
US 20030180320A1 · Darji et al. · 2003 [cited by applicant]
US 20040120962A1 · Curtiss, III et al. · 2004 [cited by applicant]
US 20040229338A1 · King · 2004 [cited by applicant]
US 20050118193A1 · Andino-Pavlovsky et al. · 2005 [cited by applicant]
US 20050180969A1 · Hardy et al. · 2005 [cited by applicant]
US 20050244375A1 · Leonard et al. · 2005 [cited by applicant]
US 20050249706A1 · Bermudes et al. · 2005 [cited by applicant]
US 20050255088A1 · Bermudes et al. · 2005 [cited by applicant]
US 20060051380A1 · Schulick et al. · 2006 [cited by applicant]
US 20070009489A1 · Bermudes et al. · 2007 [cited by applicant]
US 20070166281A1 · Kosak · 2007 [cited by applicant]
US 20070207171A1 · Dubensky et al. · 2007 [cited by applicant]
US 20070298012A1 · King et al. · 2007 [cited by applicant]
US 20080091375A1 · Brunell · 2008 [cited by applicant]
US 20080112928A1 · Loessner et al. · 2008 [cited by applicant]
US 20080124355A1 · Bermudes · 2008 [cited by applicant]
US 20090074787A1 · Gomez-Navarro et al. · 2009 [cited by applicant]
US 20090111762A1 · Roth et al. · 2009 [cited by applicant]
US 20090123426A1 · Li et al. · 2009 [cited by applicant]
US 20090169517A1 · Bermudes et al. · 2009 [cited by applicant]
US 20090175829A1 · Forbes et al. · 2009 [cited by applicant]
US 20090208534A1 · Xu et al. · 2009 [cited by applicant]
US 20090220459A1 · Fensterle et al. · 2009 [cited by applicant]
US 20100098665A1 · Leonard et al. · 2010 [cited by applicant]
US 20100135961A1 · Bermudes · 2010 [cited by applicant]
US 20120009153A1 · Guo et al. · 2012 [cited by applicant]
US 20120142080A1 · Bermudes · 2012 [cited by applicant]
US 20120171159A1 · Fensterle · 2012 [cited by applicant]
US 20120294929A1 · Roth et al. · 2012 [cited by applicant]
US 20130034559A1 · Queva et al. · 2013 [cited by applicant]
US 20130045202A1 · Irving et al. · 2013 [cited by applicant]
US 20130045525A1 · Leonard et al. · 2013 [cited by applicant]
US 20130142786A1 · Liu et al. · 2013 [cited by applicant]
US 20130150258A1 · Weichselbaum et al. · 2013 [cited by applicant]
US 20140127284A1 · Cheresh · 2014 [cited by applicant]
US 20140127816A1 · Hanson et al. · 2014 [cited by applicant]
US 20140178341A1 · Zhao et al. · 2014 [cited by applicant]
US 20140186401A1 · Diamond et al. · 2014 [cited by applicant]
US 20140212396A1 · Newman · 2014 [cited by applicant]
US 20140220661A1 · Bermudes · 2014 [cited by applicant]
US 20140242095A1 · Wang et al. · 2014 [cited by applicant]
US 20150017204A1 · Bermudes · 2015 [cited by applicant]
US 20150064215A1 · Huang et al. · 2015 [cited by applicant]
US 20150071873A1 · Biot et al. · 2015 [cited by applicant]
US 20150098897A1 · Brahmbhatt et al. · 2015 [cited by applicant]
US 20150147315A1 · Wei · 2015 [cited by applicant]
US 20150165011A1 · Lubenau · 2015 [cited by applicant]
US 20150224151A1 · Julian Gomez et al. · 2015 [cited by applicant]
US 20150232880A1 · Hemminki et al. · 2015 [cited by applicant]
US 20160184456A1 · Diamond et al. · 2016 [cited by applicant]
US 20160199422A1 · Newman · 2016 [cited by applicant]
US 20160222387A1 · Khodarev et al. · 2016 [cited by applicant]
US 20160222393A1 · Bermudes · 2016 [cited by applicant]
US 20160228523A1 · Newman · 2016 [cited by applicant]
US 20160250311A1 · Lubenau · 2016 [cited by applicant]
US 20160333355A1 · Deng et al. · 2016 [cited by applicant]
US 20160369282A1 · Li et al. · 2016 [cited by applicant]
US 20170020931A1 · Zhou et al. · 2017 [cited by applicant]
US 20170081671A1 · Diamond et al. · 2017 [cited by applicant]
US 20170081673A1 · Hanson et al. · 2017 [cited by applicant]
US 20170157239A1 · Bermudes · 2017 [cited by applicant]
US 20170275375A1 · Rossi et al. · 2017 [cited by applicant]
US 20170298362A1 · Khodarev et al. · 2017 [cited by applicant]
US 20170326235A1 · Brahmbhatt et al. · 2017 [cited by applicant]
US 20170333490A1 · Forbes et al. · 2017 [cited by applicant]
US 20180104320A1 · Gravekamp · 2018 [cited by applicant]
US 20180148729A1 · Hasty et al. · 2018 [cited by applicant]
US 20180311343A1 · Huang et al. · 2018 [cited by applicant]
US 20190008936A1 · Lubenau · 2019 [cited by applicant]
US 20190017050A1 · Thanos et al. · 2019 [cited by applicant]
US 20190017057A1 · Bermudes · 2019 [cited by applicant]
US 20190071679A1 · Khodarev et al. · 2019 [cited by applicant]
US 20190153452A1 · Diamond et al. · 2019 [cited by applicant]
US 20190307869A1 · Newman · 2019 [cited by applicant]
US 20190336544A1 · Falb et al. · 2019 [cited by applicant]
US 20200023053A1 · Bermudes · 2020 [cited by applicant]
US 20200055904A1 · Erhardt et al. · 2020 [cited by applicant]
US 20200071702A1 · Thanos et al. · 2020 [cited by applicant]
US 20200157549A1 · Diamond et al. · 2020 [cited by applicant]
US 20200215123A1 · Thanos et al. · 2020 [cited by applicant]
US 20200261572A1 · Huang et al. · 2020 [cited by applicant]
US 20200270613A1 · Thanos et al. · 2020 [cited by applicant]
US 20210030813A1 · Thanos · 2021 [cited by examiner]
US 20210113628A1 · Loughhead et al. · 2021 [cited by applicant]
US 20220017904A1 · Thanos et al. · 2022 [cited by applicant]
US 20220047649A1 · Newman · 2022 [cited by applicant]
US 20220072112A1 · Lubcnau · 2022 [cited by applicant]
US 20220112501A1 · Thanos et al. · 2022 [cited by applicant]
US 20220119824A1 · Glickman · 2022 [cited by examiner]
US 20220135980A1 · Thanos et al. · 2022 [cited by applicant]
US 20220241432A1 · Diamond et al. · 2022 [cited by applicant]
US 20220251579A1 · Hasty et al. · 2022 [cited by applicant]
US 20230226122A1 · Falb et al. · 2023 [cited by applicant]
US 20240180974A1 · Falb et al. · 2024 [cited by applicant]
AU 2005316458 · 2006 [cited by applicant]
CA 2591565 · 2006 [cited by applicant]
CA 3069523 · 2019 [cited by applicant]
CN 103468626B · 2016 [cited by applicant]
CN 106413745A · 2017 [cited by applicant]
EP 1262193 · 2002 [cited by applicant]
EP 1655370 · 2006 [cited by applicant]
EP 2270136 · 2011 [cited by applicant]
EP 3820992 · 2021 [cited by applicant]
JP 2002513287 · 2002 [cited by applicant]
WO WO9848026 · 1998 [cited by applicant]
WO WO1998048026 · 1998 [cited by applicant]
WO WO1999013053 · 1999 [cited by applicant]
WO WO1999025387 · 1999 [cited by applicant]
WO WO2000037504 · 2000 [cited by applicant]
WO WO2001025399 · 2001 [cited by applicant]
WO WO2002059292 · 2002 [cited by applicant]
WO WO2003096812 · 2003 [cited by applicant]
WO WO2005116233 · 2005 [cited by applicant]
WO WO2006066048 · 2006 [cited by applicant]
WO WO2007112518 · 2007 [cited by applicant]
WO WO2007130604 · 2007 [cited by applicant]
WO WO2008091375 · 2008 [cited by applicant]
WO WO2008156712 · 2008 [cited by applicant]
WO WO2009006450 · 2009 [cited by applicant]
WO WO2009095436 · 2009 [cited by applicant]
WO WO2010010983 · 2010 [cited by applicant]
WO WO2010045620 · 2010 [cited by applicant]
WO WO2010057009 · 2010 [cited by applicant]
WO WO2010077634 · 2010 [cited by applicant]
WO WO2011100489 · 2011 [cited by applicant]
WO WO2011150421 · 2011 [cited by applicant]
WO WO2012149364 · 2012 [cited by applicant]
WO WO2013019906 · 2013 [cited by applicant]
WO WO2013163893 · 2013 [cited by applicant]
WO WO2014189996 · 2014 [cited by applicant]
WO WO2015002969 · 2015 [cited by applicant]
WO WO2015032165 · 2015 [cited by applicant]
WO WO2015059303 · 2015 [cited by applicant]
WO WO2015108595 · 2015 [cited by applicant]
WO WO2015134722 · 2015 [cited by applicant]
WO WO2015142875 · 2015 [cited by applicant]
WO WO2015191861 · 2015 [cited by applicant]
WO WO2016025582 · 2016 [cited by applicant]
WO WO2017005773 · 2017 [cited by applicant]
WO WO2017043815 · 2017 [cited by applicant]
WO WO2017044487 · 2017 [cited by applicant]
WO WO2017123675 · 2017 [cited by applicant]
WO WO2017156349 · 2017 [cited by applicant]
WO WO2018006005 · 2018 [cited by applicant]
WO WO2018011289 · 2018 [cited by applicant]
WO WO2018045058 · 2018 [cited by applicant]
WO WO2018106754 · 2018 [cited by applicant]
WO WO2018129404 · 2018 [cited by applicant]
WO WO2018191619 · 2018 [cited by applicant]
WO WO2018191654 · 2018 [cited by applicant]
WO WO2018197621 · 2018 [cited by applicant]
WO WO2019014398 · 2019 [cited by applicant]
WO WO2019183117 · 2019 [cited by applicant]
WO WO2020014543 · 2020 [cited by applicant]
WO WO2020176809A1 · 2020 [cited by applicant]
WO WO2021097144A2 · 2021 [cited by applicant]
Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above- referenced application, filed herewith on Jul. 19, 2023, 2 pages. [cited by applicant]
Office Action, dated May 16, 2023, in connection with Japanese Patent Application No. 2022-063218 [English summary of Office Action, English translation of Office Action, and original document as issued in Japanese], 11… [cited by applicant]
Response, filed Jun. 22, 2023, to Examination Report, dated Oct. 8, 2022, in connection with Australian Patent Application No. 2019301699, 131 pages. [cited by applicant]
Examination Report, dated Jul. 8, 2023, in connection with Australian Patent Application No. 2019301699, 5 pages. [cited by applicant]
Response, filed Apr. 21, 2023, to Examiner's Report, dated Dec. 23, 2022, in connection with Canadian Patent Application No. 3,106,143, 39 pages. [cited by applicant]
Response, filed Jun. 29, 2023, to Communication pursuant to Rule 164(2)(b) and Article 94(3) EPC (Examination Report), dated Sep. 15, 2022, issued in connection with European Patent Application No. 19 745 021.6, 39 page… [cited by applicant]
Response, filed May 19, 2023, to Office Action, issued Dec. 20, 2022, in connection with Japanese Patent Application No. 2021-500579 [English instructions for response; Response as-filed in Japanese; and English transla… [cited by applicant]
Office Action, mailed Jun. 20, 2023, in connection with Japanese Patent Application No. 2021-500579 [English translation of Office Action, and Document as issued in Japanese], 5 pages. [cited by applicant]
Response, filed Jul. 11, 2023, to Office Action, mailed Jun. 20, 2023, in connection with Japanese Patent Application No. 2021-500579 [English instructions for response; documents as filed in Japanese; and English trans… [cited by applicant]
Office Action, issued May 2, 2023, in connection with Korean Patent Application No. 10-2021-7004205 [English translation of Office Action; and Document as issued in Korean], 14 pages. [cited by applicant]
Notice of Allowance, mailed Jul. 17, 2023, in connection with U.S. Appl. No. 16/520,155, 7 pages. [cited by applicant]
Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Jan. 11, 2023, 2 pages. [cited by applicant]
Allen et al., “Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model,” Cancer Immunology, Immunotherapy 67:6… [cited by applicant]
Crull et al., “Influence of infection route and virulence factors on colonization of solid tumors by [cited by applicant]
Miller et al., “Genetic diversity and population structure of the endangered marsupial [cited by applicant]
Examiner's Report, dated Dec. 14, 2022, issued in connection with Canadian Patent Application No. 3,069,523, 4 pages. [cited by applicant]
Notification of Reopening of Prosecution Due to Consideration of an Information Disclosure Statement Filed After Mailing of a Notice of Allowance, mailed Sep. 12, 2022, in connection with U.S. Appl. No. 16/520,155, 3 pa… [cited by applicant]
Office Action, dated Oct. 7, 2022, in connection with U.S. Appl. No. 16/520,155, 14 pages. [cited by applicant]
Notice of Allowance, mailed Jun. 15, 2022, in connection with U.S. Appl. No. 17/037,455, 9 pages. [cited by applicant]
Corrected Notice of Allowability, mailed Sep. 2, 2022, in connection with U.S. Appl. No. 17/037,455, 2 pages. [cited by applicant]
Notification of Reopening of Prosecution Due to Consideration of an Information Disclosure Statement Filed After Mailing of a Notice of Allowance, mailed Oct. 26, 2022, in connection with U.S. Appl. No. 17/037,455, 3 pa… [cited by applicant]
Examination Report, dated Oct. 8, 2022, in connection with Australian Patent Application No. 2019301699, 3 pages. [cited by applicant]
Examiner's Report, dated Dec. 23, 2022, in connection with Canadian Patent Application No. 3,106,143, 5 pages. [cited by applicant]
Examiner's Report, dated Dec. 9, 2022, in connection with Canadian Patent Application No. 3,176,812, 4 pages. [cited by applicant]
Office Action, issued Aug. 29, 2022, in connection with Chinese Patent Application No. 201980059088.5 [English translation of office action; and original document as issued in Chinese], 10 pages. [cited by applicant]
Communication pursuant to Rule 164(2)(b) and Article 94(3) EPC (Examination Report), dated Sep. 15, 2022, issued in connection with European Patent Application No. 19 745 021.6, 11 pages. [cited by applicant]
Office Action, issued Dec. 20, 2022, in connection with Japanese Patent Application No. 2021-500579 [English summary of Office Action; English translation of Office Action; and Document as issued in Japanese], 8 pages. [cited by applicant]
Search Report and Written Opinion, dated Sep. 2, 2022, in connection with Singapore Patent Application No. 11202100023X, 12 pages. [cited by applicant]
Office Action, issued Jun. 29, 2022, in connection with U.S. Appl. No. 16/824,500, 25 pages. [cited by applicant]
Response, filed Dec. 29, 2022, to Office Action, issued Jun. 29, 2022, in connection with U.S. Appl. No. 16/824,500, 66 pages. [cited by applicant]
Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Sep. 6, 2023, 2 pages. [cited by applicant]
Response, filed Aug. 7, 2023, to Office Action, dated Feb. 7, 2023, in connection with U.S. Appl. No. 17/037,455 [Response as filed with 3 cited references], 151 pages. [cited by applicant]
Final Office Action, dated Aug. 29, 2023, in connection with U.S. Appl. No. 17/037,455, 29 pages. [cited by applicant]
Examiner's Report, dated Jul. 25, 2023, in connection with Canadian Patent Application No. 3,106,143, 4 pages. [cited by applicant]
Office Action, dated Aug. 5, 2023, in connection with Chinese Patent Application No. 201980059088.5 [English translation of office action; and original document as issued in Chinese], 14 pages. [cited by applicant]
Decision to Grant, issued Aug. 1, 2023, in connection with Japanese Patent Application No. 2021-500579 [English reporting letter, and original document as issued in Japanese], 6 pages. [cited by applicant]
Response, filed Aug. 11, 2023, to Office Action, issued May 2, 2023, in connection with Korean Patent Application No. 10-2021-7004205 [English instructions for response; Document as filed in Korean, with cited reference… [cited by applicant]
Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, filed herewith on Jun. 14, 2022, 2 pages. [cited by applicant]
Ablasser et al., “Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP,” Nature 503(7477):530-534 (2013). [cited by applicant]
Ablasser et al., “TREX1 Deficiency Triggers Cell-Autonomous Immunity in a cGAS-Dependent Manner,” J. Immunol. 192:5993-5997 (2014). [cited by applicant]
Agbor, T. A. and McCormick, B. A., “ [cited by applicant]
Ahn et al., “Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on Sting,” J. Immunol. 193(9):4634-4642 (2014). [cited by applicant]
Ahn et al., “Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells,” Cancer Cell 33(5):862-873 (2018). [cited by applicant]
Akira et al., “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nat. Immunol. 2(8):675-680 (2001). [cited by applicant]
Aleksic et al., “Different affinity windows for virus and cancer-specific T-cell receptors—implications for therapeutic strategies,” Eur. J. Immunol. 42(12):3174-3179 (2012). [cited by applicant]
Allen et al., “CCL3 augments tumor rejection and enhances CD8 [cited by applicant]
Alshangiti et al., “Antiangiogenic therapies in non-small-cell lung cancer,” Curr. Oncol. 25(Suppl 1):S45-S58 (2018). [cited by applicant]
Anassi, E. and Ndefo, U. A., “Sipuleucel-T (Provenge) Injection: The First Immunotherapy Agent (Vaccine) for Hormone-Refractory Prostate Cancer,” P&T 36(4):197-202 (2011). [cited by applicant]
Angelakopoulos, H. and Hohmann, E. L., “Pilot Study of phoP/phoQ-Deleted [cited by applicant]
Ansel H. C., “Introduction to Pharmaceutical Dosage Forms,” Fourth Edition, Lea & Febiger, Philadelphia, 1985, p. 126. [cited by applicant]
Antonioli et al., “Immunity, inflammation and cancer: a leading role for adenosine,” Nat. Rev. Cancer 13(12):842-857 (2013). [cited by applicant]
Anwar et al., “Modulation of Biofilm-Formation in [cited by applicant]
Argyle, D. and Kitamura, T., “Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors,” Front. Immunol. 9:2629 (2018), 15 pages. [cited by applicant]
Arpaia et al., “TLR signaling is required for virulence of an intracellular pathogen,” Cell 144(5):675-688 (2011). [cited by applicant]
Auyeung et al., “Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing,” Cell 152(4):844-858 (2013). [cited by applicant]
Baban et al., “Bacteria as vectors for gene therapy of cancer,” Bioengineered Bugs 1(6):385-394 (2010). [cited by applicant]
Barber, G. N., “Cytoplasmic DNA innate immune pathways,” Immunol. Rev. 243(1):99-108 (2011). [cited by applicant]
Barber, G. N., “STING: infection, inflammation and cancer,” Nat. Rev. Immunol. 15(12):760-770 (2015). [cited by applicant]
Bastin et al., “Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies,” Biomedicines 4(3):21 (2016), 19 pages. [cited by applicant]
Bermudes et al., “Tumour-Selective [cited by applicant]
Bermudes et al., “Tumor-Targeted [cited by applicant]
Bermudes et al., “Live bacteria as anticancer agents and tumor-selective protein delivery vectors,” Curr. Opin. Drug Discov. Devel. 5(2):194-199 (2002). [cited by applicant]
Bian et al., “Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells, ” Proc. Natl. Acad. Sci. U.S.A. 113(37):E5434-E5443 (2016). [cited by applicant]
Binder et al., “Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer,” Cancer Immunol. Res. 1(2):123-133 (2013). [cited by applicant]
Blache et al., “Systemic Delivery of [cited by applicant]
Boden et al., “Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins,” Nucleic Acids Research 32(3):1154-1158 (2004). [cited by applicant]
Broadway et al., “Complete genome sequence of [cited by applicant]
Broadway et al., “Rescuing chemotaxis of the anticancer agent [cited by applicant]
Broz, P. and Monack, D. M., “Molecular Mechanisms of Inflammasome Activation during Microbial Infections,” Immunol. Rev. 243(1):174-190 (2011). [cited by applicant]
Bucarey et al., “The [cited by applicant]
Buchbinder, E. and Hodi, F. S., “Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade,” J. Clin. Invest. 125(9):3377-3383 (2015). [cited by applicant]
Burdette et al., “STING is a direct innate immune sensor of cyclic-di-GMP,” Nature 478(7370):515-518 (2011). [cited by applicant]
Carrillo, H. and Lipman, D., “The multiple sequence alignment problem in biology,” Siam J. Applied Math 48(5):1073-1082 (1988). [cited by applicant]
Carroll, V. A. and Ashcroft, M., “Targeting the molecular basis for tumour hypoxia,” Expert Rcv. Mol. Med. 7(6):1-16 (2005). [cited by applicant]
Caskey et al., “Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans,” J. Exp. Med. 208(12):2357-2366 (2011). [cited by applicant]
Chang et al., “Creating an miR30-Based shRNA Vector,” Cold Spring Harb. Protoc., doi:10.1101/pdb.prot075853, pp. 631-635 (2013). [cited by applicant]
Chatfield et al., “Use of the nirB promoter to direct the stable expression of heterologous antigens in [cited by applicant]
Chen et al., “The Neutrophil NLRC4 Inflammasomc Selectively Promotes IL-1β Maturation without Pyroptosis during Acute [cited by applicant]
Chen, L. and Han, X., “Anti-PD-1/PD-L1 therapy of human cancer: past, present and future,” J. Clin. Invest. 125(9):3384-3391 (2015). [cited by applicant]
Chi et al., “Anti-tumor Activity of Toll-Like Receptor 7 Agonists,” Frontiers in Pharmacology 8:304 (2017), 10 pages. [cited by applicant]
Chiocca, E.A. and Rabkin, S.D., “Oncolytic Viruses and Their Application to Cancer Immunotherapy,” Cancer Immunol. Res. 2(4):295-300 (2014). [cited by applicant]
Chiu et al., “RNA polymerase III detects cytosolic DNA and induces type-I interferons through the RIG-I pathway,” Cell 138(3):576-591 (2009). [cited by applicant]
Chorobik et al., “ [cited by applicant]
Chowdhury et al., “Programmable bacteria induce durable tumor regression and systemic antitumor immunity,” Nature Medicine 25(7):1057-1063 (2019). [cited by applicant]
Chung et al., “Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155,” Nucleic Acids Res. 34(7):e53 (2006), 14 pages. [cited by applicant]
Civril et al., “Structural mechanism of cytosolic DNA sensing by cGAS,” Nature 498(7454):332-337 (2013). [cited by applicant]
Clairmont et al., “Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of [cited by applicant]
Clevers, H. and Nusse, R., “Wnt/β-Catenin Signaling and Disease,” Cell 149:1192-1205 (2012). [cited by applicant]
Coburn et al., “Type III Secretion Systems and Disease,” Clinical Microbiology Reviews 20(4):535-549 (2007). [cited by applicant]
Copier, J. and Dalgleish, A., “Whole-cell vaccines: A failure or a success waiting to happen?,” Curr. Opin. Mol. Ther. 12(1):14-20 (2010) [abstract]. [cited by applicant]
Corrales et al., “Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity,” Cell Rep. 11(7):1018-1030 (2015). [cited by applicant]
Crull et al., “Biofilm formation by [cited by applicant]
Dang et al., “Combination bacteriolytic therapy for the treatment of experimental tumors,” Proc. Natl. Acad. Sci. U.S.A. 98(26):15155-15160 (2001). [cited by applicant]
Datsenko, K. A. and Wanner, B. L., “One-step inactivation of chromosomal genes in [cited by applicant]
Dean et al., “Sequence requirements for plasmid nuclear import,” Exp. Cell Res. 253(2):713-722 (1999). [cited by applicant]
Del Solar et al., “Replication and Control of Circular Bacterial Plasmids,” Microbiology and Molecular Biology Reviews 62(2):434-464 (1998). [cited by applicant]
Deng et al., “A New VISTA on combination therapy for negative checkpoint regulator blockade,” Journal for Immuno Therapy of Cancer 4:86 (2016), 7 pages. [cited by applicant]
Diamond et al., “Type I interferon is selectively required by dendritic cells for immune rejection of tumors,” J. Exp. Med. 208(10):1989-2003 (2011). [cited by applicant]
Dinarello, C.A., “Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock,” Chest 112(6 Suppl):321S-329S (1997). [cited by applicant]
Diner et al., “The innate immune DNA sensor cGAS produces a non-canonical cyclic-di-nucleotide that activates human STING,” Cell Rep. 3(5):1355-1361 (2013). [cited by applicant]
DiPetrillo et al., “Safety and immunogenicity of phoP/phoQ-deleted [cited by applicant]
Di Domenico et al., “Biofilm Producing [cited by applicant]
Dotti et al., “Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40 [cited by applicant]
Dreher et al., “Genetic background of attenuated [cited by applicant]
Dubinett et al., “Chemokines: Can Effector Cells be Re-directed to the Site of Tumor?,” Cancer J. 16(4):325-335 (2010). [cited by applicant]
Durfee et al., “The complete genome sequence of [cited by applicant]
Edwards et al., “DNA Damage Repair Genes Controlling Human Papillomavirus (HPV) Episome Levels under Conditions of Stability and Extreme Instability,” PLoS One 8(10):e75406 (2013), 16 pages. [cited by applicant]
Eisenstark et al., “Development of [cited by applicant]
Esebanmen, G.E. and Langridge, W.H.R., “The role of TGF-beta signaling in dendritic cell tolerance,” Immunol. Res. 65(5):987-994 (2017). [cited by applicant]
Fabbi et al., “Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP,” J. Leukoc. Biol. 97:665-675 (2015). [cited by applicant]
Faulds-Pain et al., “Flagellin Redundancy in [cited by applicant]
Felgner et al., “aroA-Deficient [cited by applicant]
Felgner et al., “Optimizing [cited by applicant]